Tumor suppressor p16 INK4a controls oncogenic K-Ras function in human pancreatic cancer cells

Cancer Science

Volumn 103, Issue 2, 2012, Pages 169-175

  Rabien, Anja ^a   Sanchez Ruderisch, Hugo ^a   Schulz, Petra ^a   Otto, Noreen ^a,b   Wimmel, Anja ^a   Wiedenmann, Bertram ^a   Detjen, Katharina M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; PROTEIN P21;

ANOIKIS; ARTICLE; CANCER CELL CULTURE; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN STABILITY; BIOSYNTHESIS; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL TRANSFORMATION; COLON TUMOR; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANOIKIS; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENE PROTEIN P21(RAS); PANCREATIC NEOPLASMS;

EID: 84856478313     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02140.x     Document Type: Article

References (46)

1. Hruban RH, Maitra A, Schulick R et al. Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res 2008; 2: S10-5.
2. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6.
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
4. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-4.
5. Scarlett CJ, Salisbury EL, Biankin AV, Kench J. Precursor lesions in pancreatic cancer: morphological and molecular pathology. Pathology 2011; 43: 183-200.
6. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997; 237: 7-13.
7. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55.
8. Plath T, Detjen K, Welzel M et al. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol 2000; 150: 1467-78.
9. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-7.
10. Derouet M, Wu X, May L et al. Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo. Neoplasia 2007; 9: 536-45.
11. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-31.
12. Malumbres M, Barbacid M. RAS oncogenes: the first 30years. Nat Rev Cancer 2003; 3: 459-65.
13. Ellis CA, Clark G. The importance of being K-Ras. Cell Signal 2000; 12: 425-34.
14. Ashery U, Yizhar O, Rotblat B, Kloog Y. Nonconventional trafficking of Ras associated with Ras signal organization. Traffic 2006; 7: 119-26.
15. Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol 2009; 5: 105-16.
16. Aguirre AJ, Bardeesy N, Sinha M et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-26.
17. Palmero I, Serrano M. Induction of senescence by oncogenic Ras. Methods Enzymol 2001; 333: 247-56.
18. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995; 267: 249-52.
19. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
20. Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004; 64: 5659-63.
21. Guerra C, Mijimolle N, Dhawahir A et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-20.
22. Hingorani SR, Petricoin EF, Maitra A et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-50.
23. Tuveson DA, Shaw AT, Willis NA et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-87.
24. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-49.
25. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007; 14: 224-32.
26. Lee KE, Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010; 18: 448-58.
27. Yamakoshi K, Takahashi A, Hirota F et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol 2009; 186: 393-407.
28. Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999; 80: 553-8.
29. Schulz P, Scholz A, Rexin A et al. Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis. Br J Cancer 2008; 99: 110-7.
30. Kalthoff H, Schmiegel W, Roeder C et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289-98.
31. Bond J, Jones C, Haughton M, deMicco C, Kipling D, Wynford-Thomas D. Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation. Exp Cell Res 2004; 292: 151-6.
32. Ashery U, Yizhar O, Rotblat B et al. Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch. Cell Mol Neurobiol 2006; 26: 471-95.
33. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 34922-30.
34. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005; 65: 7292-300.
35. Shalom-Feuerstein R, Plowman SJ, Rotblat B et al. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res 2008; 68: 6608-16.
36. Li J, Mahajan A, Tsai MD. Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 2006; 45: 15168-78.
37. Abankwa D, Gorfe AA, Inder K, Hancock JF. Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci USA 2010; 107: 1130-5.
38. Inder KL, Lau C, Loo D et al. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction. J Biol Chem 2009; 284: 28410-9.
39. Kim SE, Yoon JY, Jeong WJ et al. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation. J Cell Sci 2009; 122: 842-8.
40. Ulsh LS, Shih TY. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs. Mol Cell Biol 1984; 4: 1647-52.
41. Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D. Differential modification of Ras proteins by ubiquitination. Mol Cell 2006; 21: 679-87.
42. Ballester R, Furth ME, Rosen OM. Phorbol ester- and protein kinase C-mediated phosphorylation of the cellular Kirsten ras gene product. J Biol Chem 1987; 262: 2688-95.
43. Bivona TG, Quatela SE, Bodemann BO et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell 2006; 21: 481-93.
44. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 1998; 7: 515-21.
45. Ferbeyre G. Barriers to Ras transformation. Nat Cell Biol 2007; 9: 483-5.
46. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007; 9: 493-505.